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IL-1R1 Signaling Facilitates Munro’s Microabscess
Formation in Psoriasiform Imiquimod-Induced Skin
Inflammation
Mireia Uribe-Herranz1, Li-Hua Lian1, Kirsten M. Hooper1, Katelynn A. Milora1 and Liselotte E. Jensen1
Munro’s microabscesses contain polymorphonuclear leukocytes and form specifically in the epidermis of
psoriasis patients. The mechanism whereby the neutrophils are recruited into the epidermis is poorly under-
stood. Using a combination of human and mouse primary keratinocyte cell cultures and the imiquimod-induced
psoriasis-like mouse model of skin inflammation, we explored the role of IL-1 signaling in microabscess
formation. In vitro imiquimod stimulated production of IL-1a and neutrophil recruiting chemokines. Imiquimod-
activated chemokine expression was dependent upon adenosine signaling and independent of IL-1a and IL-1
receptor type 1 (IL-1R1); nevertheless, IL-1a could enhance chemokine expression initiated by imiquimod. Topical
application of imiquimod in vivo led to epidermal microabscess formation, acanthosis, and increased IL-1a and
chemokine expression in the skin of wild-type mice. However, in IL-1R1-deficient mice these responses were
either absent or dramatically reduced. These results demonstrate that IL-1a and IL-1R1 signaling is essential for
microabscess formation, neutrophil recruiting chemokine expression, and acanthosis in psoriasis-like skin
inflammation induced by imiquimod.
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INTRODUCTION
Munro’s microabscesses are a characteristic hallmark of
psoriasis pathology (Munro, 1898; Steffen, 2002). These sites
of inflammation contain polymorphonuclear leukocytes and
form specifically in the epidermal layer of the skin (Munro,
1898; Steffen, 2002). Given the localization of these
microabscesses within the epidermis keratinocytes are likely
to have a role in their development; however, the mechanism
whereby this interesting phenomenon develops is
incompletely characterized. Psoriasis is a chronic inflam-
matory condition of the skin. In addition to the presence of
Munro’s microabscesses the disease is characterized by acan-
thosis, hyperkeratosis, and parakeratosis of the epidermis, as
well as a mixed inflammatory infiltrate and increased
vascularization in the dermis. Genome-wide expression
profiling has identified several chemokines, e.g., CXCL1 and
IL-8, which are expressed at higher levels in psoriatic skin
compared with normal skin (Bowcock et al., 2001; Zhou
et al., 2003; Lew et al., 2004).
IL-1 represents the two pleiotropic cytokines IL-1a and
IL-1b, of which IL-1a is the predominant form expressed in
keratinocytes (Olaru and Jensen (2010b); Lian et al. (2012);
and references therein). Extracellular IL-1a and IL-1b
activate gene expression via the IL-1 receptor type I (IL-1R1)
and a complex signaling cascade leading to activation of
transcription factors such as NF-kB and AP-1 (Jensen,
2010). Interestingly, the gene expression profiles of skin
biopsies from psoriasis patients strongly resemble that of the
keratinocyte transcriptome induced in response to IL-1a (Mee
et al., 2007; Yano et al., 2008). Previously IL-1a and IL-1b
have been linked to several of the phenotypes observed in
psoriasis, e.g., proliferation and cell differentiation (see
Sanmiguel et al. (2009) for reference), but their potential
role in formation of Munro’s microabscesses have not been
explored.
Aldara (imiquimod cream) is Food and Drug Administration
approved for the treatment of human papillomavirus genital
warts, actinic keratoses, and basal cell carcinomas. The drug
has been known for some time to cause psoriasis-like disease
in some patients and trigger outbreaks in patients with
psoriasis (Gilliet et al., 2004; Wu et al., 2004; Fanti et al.,
2006; Rajan and Langtry, 2006; van der Fits et al., 2009; Patel
et al., 2011). In 2009 van der Fits et al. reported that
application of imiquimod cream to the back skin of mice
caused phenotypes with remarkable resemblance to human
psoriasis pathology, including the presence of Munro’s
microabscesses. It was further established that the disease in
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mice was dependent upon the IL-23IL-17 axis (van der Fits
et al., 2009), which is now widely recognized for its
involvement in human psoriasis (Zaba et al., 2009; Tonel
et al., 2010). Subsequent studies of the model using
microarray expression analyses have revealed a striking
overlap with the expression profiles of human psoriatic skin
(Swindell et al., 2011). Imiquimod is best known as a ligand
for TLR7 and TLR8; however, the drug can also modulate an
adenosine receptor signaling pathway (Scho¨n et al., 2006)
and has cytotoxic effects upon cells at high concentrations
(reviewed in Scho¨n and Scho¨n, 2007). We recently
characterized the role of IL-1a as an intermediate signaling
molecule between TLR2 and neutrophil-targeting chemokine
expression in keratinocytes (Olaru and Jensen, 2010b), and
therefore hypothesized that one or more forms of IL-1 may
have a role in Munro’s microabscess formation. Here we
demonstrate that in the imiquimod-induced psoriasis-like skin
disease mouse model Munro’s microabscess formation is
dependent upon IL-1R1 signaling. Furthermore, we show
that keratinocytes express neutrophil-targeting chemokines in
response to imiquimod. Activated keratinocytes also release
IL-1a, and IL-1a can enhance chemokine expression in
response to imiquimod.
RESULTS
Human and mouse keratinocytes produce neutrophil-targeting
chemokines in response to imiquimod in vitro
As Munro’s microabscesses specifically occur in the epidermis
comprised of keratinocytes, we wished to identify signaling
pathways governing the mechanism whereby keratinocytes
recruit neutrophils to these sites of inflammation. The two
neutrophil-targeting chemokines CXCL1 and IL-8 have been
reported to be overexpressed in psoriatic skin (Bowcock et al.,
2001; Zhou et al., 2003; Lew et al., 2004). Our previous
studies of the role of keratinocytes as the first responders to
stress and injury have established that human keratinocytes
produce the neutrophil chemotactic CXCL1, CXCL2, and IL-8
when sensing TLR ligands (Olaru and Jensen, 2010b), and
therefore we focused our analyses on this subset of
chemokines. Initial studies established that at concentrations
up to 50mg ml1, imiquimod induced expression of the
CXCL1, CXCL2, and IL-8 mRNAs in concentration-
dependent manners (Figure 1, upper panels). The gene
expression appeared to be biphasic as decreases in mRNA
levels were observed between the 3- and 24-hour time points
(Figure 1, upper panels). Expression of the chemokines was
also concentration dependent, and levels in the medium
increased throughout the duration of the experiment
(Figure 1, lower panels). Similar observations were made for
CXCL1 and CXCL2 using mouse primary keratinocytes (data
not shown, mice do not have IL-8).
Although chemokine expression was observed with
lower levels of imiquimod, at higher concentrations imiqui-
mod was clearly toxic to cells as protein levels actually
significantly decreased when cells were treated with imiqui-
mod (Figure 1, 250mg ml 1). This is in agreement with
previously reported cytotoxicity of imiquimod (Scho¨n and
Scho¨n, 2007).
IL-1a is released by imiquimod-treated human and mouse
keratinocytes in vitro
Previously we reported that keratinocytes express and release
IL-1a and IL-1b in response to TLR ligands (Olaru and Jensen,
2010b). We therefore examined IL-1a and IL-1b expression by
keratinocytes treated with imiquimod. As described above, the
highest levels of imiquimod led to reduced mRNA and protein
expression (Figure 2a). This is likely due to the cytotoxic effect
of imiquimod and relatively short half-lives of the IL-1a and
IL-1b mRNAs (Kang et al., 1996). At lower concentrations
of imiquimod both the cytokine mRNAs were induced by
imiquimod in concentration and time-dependent manners
(Figure 2a (human keratinocytes) and data not shown (mouse
keratinocytes)). Increased levels of the IL-1a cytokine could be
detected in the culture medium as early as 3 hours after the
addition of imiquimod (Figure 2a). This appears to be earlier
than the loss of membrane potential as determined by
measuring lactate dehydrogenase (LDH; Figure 2b). Further-
more, reduced cell density was observed after 24 hours
(data not shown). IL-1b could not be detected in conditioned
medium from the above keratinocyte cultures (data not
shown).
Imiquimod-induced chemokine expression is independent of
IL-1a signaling in human and mouse keratinocytes in vitro
Our previous studies have established that IL-1a is an inter-
mediate signaling molecule between TLR2 and the neutrophil-
targeting chemokines, CXCL1, CXCL2 and IL-8 (Olaru and
Jensen, 2010b). Therefore, we hypothesized that a similar
mechanism would be responsible for the imiquimod-induced
chemokine expression, i.e., chemokine expression would be
dependent upon IL-1 release from cells and subsequent
engagement of the IL-1 signaling receptor, IL-1R1. IL-1- and
polyinosinic-polycytidylic acid (poly(I:C))–induced chemokine
expression was significantly reduced when human
keratinocytes were cotreated with an IL-1a-neutralizing
antibody compared with cells receiving an isotype-matched
control antibody (Figure 3a). Surprisingly, cells treated with
imiquimod and the IL-1a-neutralizing antibody responded
equally well as control cells treated with isotype-matched Ig
and imiquimod (Figure 3a). Interestingly, the constitutive
(medium only) production of CXCL1, CXCL2, and IL-8 was
reduced in the presence of the IL-1a-neutralizing antibody
when cultures were continued for 24 hours (Figure 3b). The
role of IL-1R1 signaling was further explored in wild-type and
IL-1R1 knockout (KO) mouse primary keratinocytes. Constitu-
tive chemokine production by IL-1R1 KO cells was lower than
that observed from wild-type cells (Figure 3c (medium) and
Supplementary Figure S1 online). Interestingly, the fold
increase in chemokine expression in response to imiquimod
was not significantly different between the wild-type (2- and
5-fold changes in CXCL1 and CXCL2, respectively) and IL-1R1
KO cells (3- and 8-fold changes in CXCL1 and CXCL2,
respectively, Figure 3c). These observations are in agreement
with the experiments involving human cells and IL-1a-neu-
tralizing antibodies (Figure 3a and b). Overall, the data suggest
that cultured keratinocytes can express neutrophil-targeting
chemokines in response to imiquimod independent of their
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capacity to signal through IL-1R1 expression. However, IL-1
signaling appears to be important for the constitutive baseline
chemokine production.
IL-1a and imiquimod have additive effects upon chemokine
expression in human and mouse keratinocytes in vitro
Our earlier studies have demonstrated that IL-1 can cooperate
with IFN-g and tumor necrosis factor-a to drive chemokine
expression in keratinocytes (Sanmiguel et al., 2009). We
therefore conducted experiments in which cells were treated
with medium, imiquimod alone, IL-1a alone, or imiquimod
with IL-1a. Curiously, these studies revealed that the single
agents (imiquimod versus IL-1a) affected the different
chemokines in distinct manners (Figure 3d and e). Although
CXCL1 was most potently induced by IL-1a, IL-8 was more
dramatically regulated by imiquimod (Figure 3d) and CXCL2
appeared to be equally regulated by the two agents
(Figure 3e). This may suggest that expression of the chemo-
kines is activated through different mechanisms, and imiqui-
mod and IL-1a modulate these in distinct ways.
Further analyses of costimulation of cells with both imiqui-
mod and IL-1a (Figure 3d and e) revealed that CXCL1, CXCL2,
and IL-8 expression was enhanced compared with cells
treated with a single agent. The enhancement appeared to
0
20
40
60
80
0
2
4
6
8
10
12
*
*
*
*
*
*
*
***
******
* *
*
*
*
*
*
* *
*
*
*
*
*
*
***
*
*
*
*
*
*
*
Fo
ld
 c
ha
ng
e 
in
m
R
N
A 
le
ve
l
0
50
100
150
200
250
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
0
0.5
1.0
1.5
2.0
*
*
*
*
*
*
*
*
***
***
0
0.5
1.0
1.5
2.0
2.5
3.0
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Pr
ot
ei
n 
le
ve
l (n
g m
l–1
)
0
0.2
0.4
0.6
0.8
1.0
*
*
*
*
*
*
*
*
*
*
**
*
CXCL1 CXCL2 IL-8
2505050 2505050 2505050
Imiquimod (μg ml–1)Imiquimod (μg ml–1)Imiquimod (μg ml–1)
24 Hours6 Hours3 Hours1 Hour
Figure 1. Expression of neutrophil-targeting chemokines is elevated in imiquimod-treated human primary keratinocytes in vitro. Cells were treated with medium
only or imiquimod and RNA, and conditioned medium collected as indicated. Levels of CXCL1, CXCL2, and IL-8 mRNA (top row) and protein (bottom row) were
determined using real-time reverse transcriptase PCR and ELISA, respectively. Levels of messenger RNA (mRNA) are represented as fold change (mean±SD)
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Fo
ld
 c
ha
ng
e 
in
m
R
N
A 
le
ve
l
Pr
ot
ei
n 
le
ve
l (p
g m
l–1
)
Imiquimod (μg ml–1)
IL-1β
0
100
200
300
400
500
*
*
*
*
*
*
*
*
*
*
0
2
4
6
8
10
*
*
**
*
*
*
*
*
***
*
*
*
*
*
*
0
1
2
3
4
*
*
*
*
*
*
*
**
*
*
Not detectable
Imiquimod (μg ml–1)
LD
H
 re
le
as
e 
(fo
ld
 c
ha
ng
e)
M
ed
iu
m
*
*
6 Hours
IL-1α
2505050
3.0
2.5
2.0
1.5
1.0
0.5
0
Im
iq
ui
m
od
(50
 μg
 m
l–1
)
Im
iq
ui
m
od
(10
 μg
 m
l–1
)
24 Hours2505050
24 Hours6 Hours3 Hours1 Hour
Figure 2. Human primary keratinocytes produce and release elevated levels of IL-1a in response to imiquimod in vitro. Cells were treated with medium or
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be additive as, e.g., 125 and 225 pg ml1 of CXCL1 was
expressed in response to imiquimod and IL-1a, respectively,
and 345 pg ml1 was expressed when imiquimod and IL-1a
were added together (Figure 3d). The additive effects of
imiquimod and IL-1a upon chemokine expression may further
suggest that these activators of gene expression act through
independent signaling pathways.
Chemokine, but not IL-1a, secretion is induced by imiquimod via
modulation of an adenosine receptor/adenylate cyclase pathway
in human keratinocytes in vitro
It has previously been reported that imiquimod can activate
gene expression in epithelial cells, including keratinocytes, via
its association with adenosine receptors and modulation of
downstream adenylate cyclase activity (Scho¨n et al., 2006;
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Figure 3. Imiquimod and IL-1 have independent and additive effects upon chemokine expression in vitro. (a) Primary human keratinocytes were pretreated for
30 minutes with neutralizing anti-human IL-1a IgG (black bars) or isotype-matched IgG (white bars) before the addition of medium only, 50mg ml1 imiquimod,
10 ng ml1 human IL-1a, or 25mg ml1 poly(I:C). Chemokine expression was examined using ELISA (mean±SD) after 6 hours. (b) Human keratinocytes were
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forskolin, 80mM CV 1808, or vehicle control for 30 minutes before addition of medium only (white bars) or 50mg ml1 imiquimod (black bars). Protein secretion
was determined using ELISA (mean±SD). *Po0.05; **Po0.01; ***Po0.001 (compared with (a–e) medium only, (f–g) equivalent vehicle control or as indicated).
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Kan et al., 2012). We found that ligands for the adenosine A2
receptor (CV 1808) and adenylate cyclase (forskolin)
significantly reduced imiquimod-induced chemokine expres-
sion compared with vehicle control–treated cells (Figure 3f).
One exception from this was CV 1808, which enhanced
expression of CXCL1 (Figure 3f). This may suggest involve-
ment of multiple adenosine receptors. The ligands affected
constitutive expression of chemokines in some experiments
(CXCL1 and CXCL2, Figure 3f); however, this effect was not
consistently observed in all experiments (data not shown).
Interestingly, IL-1a expression was not affected by either CV
1808 or forskolin (Figure 3g). This suggests that imiquimod
activates several different pathways with differential effects
upon cytokine and chemokine expression.
Topical application of imiquimod in vivo stimulates release of
IL-1a and IL-1b from mouse skin
To examine the in vivo role of IL-1 signaling and neutrophil-
targeting chemokines such as CXCL1 and CXCL2 in formation
of Munro’s microabscesses, we employed the imiquimod-
induced psoriasis-like mouse model of skin inflammation (van
der Fits et al., 2009). It has previously been shown that aged
(418 months) mice produce elevated levels of IL-1a in the
skin following a 7-day regiment of imiquimod application
(Barland et al., 2004). We first examined secretion of IL-1a
and IL-1b from explanted skin collected from young wild-type
mice treated with imiquimod for 2 days (Figure 4a and b).
Levels of IL-1a released from imiquimod-treated skin were
significantly higher than that from untreated mice (Figure 4b).
A modest, but statistically significant, increase in IL-1b was
also observed after 4 days; however, levels of IL-1b were
dramatically lower than the IL-1a levels (Figure 4b). This
opens the possibility that extracellular IL-1 is involved in
initiating pathology in imiquimod-induced skin inflammation.
Epidermal microabscess formation in mice is dependent upon
IL-1R1 in vivo
As imiquimod-treated skin released elevated levels of IL-1
(Figure 4b), we next examined the role of IL-1 signaling in the
formation of Munro’s microabscesses in wild-type and IL-1R1
KO mice. Following imiquimod treatment the presence of
cells in the stratum corneum of wild-type mice could be
identified by hematoxylin and eosin (H&E) staining (Figure 4c,
Figure 4. IL-1aIL-1R1 signaling is involved in formation of Munro’s
microabscesses in vivo. (a) Timeline for imiquimod-induced psoriasis-like skin
inflammation model. Denuded mice were treated with imiquimod on days 1
and 2 (arrowheads), and skin collected (arrows) either 6 hours post treatment
on day 2 or 2 days post treatment (day 4). Untreated skin from control mice
was collected on day 1. (b) Levels of IL-1a (black symbols) and IL-1b (white
symbols) released from wild-type explanted skin were measured using ELISA.
Circles, triangles, and diamonds indicate untreated, day 2, and day 4 time
points, respectively. (c–d) Wild-type (WT) and IL-1 receptor type 1 knockout
(IL-1R1 KO) mice were treated with imiquimod on days 1 and 2, and skin
collected on day 4. Control untreated skin was collected on day 1 (n¼3–4 per
group). (c) Skin sections were examined using hematoxylin and eosin (H&E)
staining or immunohistochemistry for the granulocyte-specific antigen Ly-6G/
Ly-6C. Arrows indicate positions of Munro’s microabscesses at the top of the
epidermis. Arrowhead indicates presence of intradermal granulocytes.
Bars¼ 100mm. (d) Wild-type (WT, black symbols) and IL-1R1 KO (KO, white
symbols) mice were treated with imiquimod (squares) or left untreated (circles).
Levels of IL-1a and IL-1b released from the skin were examined using ELISA.
*Po0.05; ***Po0.001.
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WT, day 4, H&E, arrow). These cells were not present in
untreated mice (Figure 4c, WT, day 1) or IL-1R1 KO mice
(Figure 4c, KO, day 4, H&E). Further immunohistochemical
analyses using the granulocyte-specific cell marker Ly-6G/Ly-
6C revealed that these epidermis/stratum corneum infiltrating
cells were neutrophils (Figure 4c, day 4, Ly-6G/Ly-6C,
arrows). Granulocytes could also be identified in the dermis
of imiquimod-treated wild-type mice (Figure 4c, arrowhead),
but not in IL-1R1 KO mice. These observations establish that
IL-1R1 signaling is required for the formation of Munro’s
microabscesses.
IL-1R1 signaling regulates additional psoriasis-related
phenotypes in mice in vivo
Further examination of imiquimod-treated skin revealed that
IL-1R1 KO mice had reduced acanthosis and parakeratosis
compared with wild-type mice (Figure 4c). Reduced prolifera-
tion of the IL-1R1 KO basal keratinocytes was confirmed
through detection of proliferating cell nuclear antigen
(Supplementary Figure S2 online). Antibodies for keratin 1
did not stain the bottom two layers of proliferating cells in
wild-type mice; however, in IL-1R1 only a single layer of cells
remained unstained (Supplementary Figure S2 online). IL-1R1
deficiency did not affect vascularization of the dermis
(Supplementary Figure S2 online). The numbers of dermal
macrophages and epidermal T cells also appeared similar in
wild-type and IL-1R1 KO mice (Supplementary Figure S2
online).
It has previously been shown that IL-1 has an essential role
in costimulating, in conjunction with IL-23, dermal gd
T cells to produce IL-17 (Cai et al., 2011). We observed a
few dermal T cells in wild-type mice and possibly fewer cells
were found in IL-1R1 KO mice (Supplementary Figure S2
online). However, the level of dermal infiltration by T cells
was too low to make a definitive conclusion regarding
differences between mouse strains. It should be noted
that we here examined an early stage of skin inflammation
in the employed mouse model. Hence, the observed inflam-
mation was less than that observed when mice were
treated for 5–6 days as reported previously (van der Fits
et al., 2009) and our unpublished observations. Overall, IL-
1R1 appears to differentially regulate several, but not all,
psoriasiform phenotypes in the imiquimod-induced skin
inflammation model.
IL-1a and IL-1b expression is regulated via IL-1R1 in vivo in mice
and in vitro in human keratinocytes
Previous array studies performed by others and in our
laboratory have suggested that IL-1 can stimulate expression
of the IL-1a and IL-1b mRNAs in keratinocytes; however, the
array data were not validated (Yano et al., 2008; Sanmiguel
et al., 2009). Here we found that following imiquimod
treatment secreted levels of IL-1a and IL-1b were lower in
IL-1R1 KO mice than in wild-type mice (Figure 4d). There
were no significant differences between constitutive produc-
tion of the IL-1 cytokines in untreated mice (Figure 4d).
Interestingly, levels of IL-1b were not induced by imiquimod
in IL-1R1 KO mice (Figure 4d). This could suggest that the
source of IL-1b protein found in vivo, but not in vitro, is the
neutrophils that are poorly recruited to the skin in IL-1R1 KO
mice. In vitro experiments confirmed that IL-1-treated kerati-
nocytes express elevated levels of both IL-1a and IL-1b
mRNAs (Supplementary Figure S3 online). To summarize,
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Figure 5. IL-1 receptor type 1 (IL-1R1) signaling is essential for constitutive
and imiquimod-induced chemokine expression required for granulocyte
recruitment in vivo. (a) Wild-type (WT, black symbols) and IL-1R1 knockout
(KO, white symbols) mice were treated with imiquimod (squares) or left
untreated (circles) as described in Figure 4c (n¼ 4). Levels of CXCL1 and
CXCL2 released from the skin were examined using ELISA. *Po0.05;
***Po0.001. (b) IL-1R1 KO mice were treated with imiquimod containing,
phosphate-buffered saline (PBS), CXCL1, or CXCL2 (25 ng protein per mouse)
following the schedule described in Figure 4c. Neutrophils were identified
using immunohistochemistry for Ly-6 G/Ly-6C. Arrows indicate positions of
Munro’s microabscesses in the epidermis. Bars¼ 100mm.
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IL-1R1 signaling has an important role in regulating expression
of IL-1 cytokines.
IL-1R1 KO mice produce reduced levels of CXCL1 and CXCL2
in vivo
To further explore the in vivo mechanism whereby IL-1
signaling may facilitate recruitment of neutrophils to the
epidermis, we measured levels of CXCL1 and CXCL2 secreted
from untreated and imiquimod-treated wild-type and IL-1R1
KO skin. Levels of both CXCL1 and CXCL2 were upregu-
lated when wild-type mice were treated with imiquimod
(Figure 5a, black symbols). This increase in chemokine
expression was not observed in IL-1R1 KO mice (Figure 5a,
white symbols). Interestingly, CXCL1 and CXCL2 levels in
untreated IL-1R1 KO mice were significantly lower than those
observed in wild-type mice (Figure 5a, circles). This is in
agreement with our in vitro observations above demonstrating
that neutralization of IL-1a or elimination of IL-1R1 reduces
the constitutive production of chemokines (Figure 3b–c).
Overall, these experiments establish that IL-1IL-1R1 signaling
has an essential role in regulation of chemokine expression
in vivo.
Topically applied CXCL1 and CXCL2 can rescue Munro’s
microabscess formation in vivo in IL-1R1 KO mice
As we observed that CXCL1 and CXCL2 levels were
significantly lower in IL-1R1 KO mice than in wild-type mice,
we tested whether addition of recombinant chemokines
to the imiquimod cream could rescue the recruitment of
neutrophils to the epidermis. On the basis of the data
presented in Figure 5a, we estimated that the constitutive
chemokine production in wild-type mice was 8 ng cm 2 and
we therefore treated the mice with physiologically relevant
4 ng of chemokine per cm2. Ly-6G/Ly-6C-positive cells were
observed in the upper layers of the epidermis of IL-1R1 KO
mice treated with either CXCL1 or CXCL2 in combination with
imiquimod, but not in mice treated with imiquimod and
phosphate-buffered saline (Figure 5b). This suggests that the
levels of CXCL1 and CXCL2 chemokines produced by IL-1R1
KO are insufficient to recruit neutrophils to the epidermis and
further establishes IL-1 signaling as an essential component of
this process.
DISCUSSION
Psoriasis lesions typically contain Munro’s microabscesses in
the epidermis (Munro, 1898; Steffen, 2002). We have here
established that in the imiquimod-induced psoriasis-like skin
inflammation mouse model formation of neutrophil
containing microabscesses is dependent upon IL-1R1
(Figure 4c). Our data also demonstrate that IL-1 signaling
through IL-1R1 regulates both constitutive and imiquimod-
induced chemokine expression involved in neutrophil
recruitment in vivo (Figures 4 and 5). Neutrophils express IL-
1R1 and it could be speculated that ablation of IL-1R1 would
impair functionality of the neutrophils. However, this does
not appear to be the case as topical application of CXCL1
or CXCL2 can rescue the formation of microabscesses
(Figure 5b). Interestingly, while this manuscript was under
revision an advance online publication reported that
mice lacking the IL-17 receptor A (IL-17RA) still develop
psoriasiform disease in the imiquimod-induced skin inflam-
mation model (El Malki et al., 2012). The involvement
of the IL-1R1 signaling pathway in disease pathology as
shown here in Figure 4 and Supplementary Figure S2 online
explain, at least in part, why IL-17RA KO mice still exhibit
phenotypes.
Our in vitro studies revealed that imiquimod directly
induces chemokine expression independent of IL-1 and/or
IL-1R1 in keratinocytes through an adenosine receptor signal-
ing pathway (Figure 3). Curiously, in vivo this IL-1R1-inde-
pendent pathway appears to be absent as IL-1R1 KO mice fail
to increase their chemokine expression in response to imiqui-
mod (Figure 5a). It has been demonstrated that the skin
commensal bacteria Staphylococcus epidermidis can suppress
signaling from TLR3 via upregulation of TRAF1 (Lai et al.,
2009). The pharmaceutical formulation of imiquimod used
here is designed to carry compounds into the skin. During
disease progression the barrier function of the skin is
significantly compromised, e.g., the skin becomes dry and
flaky. Hence, it is plausible that the cream carries S.
epidermidis, or byproducts from the bacteria, into the skin
with anti-inflammatory outcome, e.g., upregulation of TRAF1.
Further studies are required to determine whether the IL-1R1-
independent imiquimod-induced signaling pathway is absent
or present, but potentially suppressed, in vivo.
Given the apparent absence of the IL-1R1-independent
pathway in vivo an interesting remaining question is how
imiquimod stimulates release of IL-1a from the keratinocytes.
Keratinocytes do not express TLR7 and TLR8 (Olaru and
Jensen (2010a) and references therein); the best-known
receptors for imiquimod. Our in vitro data illustrate that
high concentrations (250mg ml 1) of imiquimod are toxic to
the keratinocytes (Figures 1 and 2); however, this toxicity does
not give rise to elevated extracellular IL-1a (Figure 2a, levels
are actually decreased). At lower concentrations loss of cell
membrane potential is observed during extended incubation
times (Figure 2b, 24 hours). However, extracellular IL-1a can
be observed as early as 3–6 hours post treatment (Figure 2a),
suggesting that this cell death is not the cause of IL-1a release.
In vivo there are no apparent signs of damage to the
epidermis; in fact acanthosis of the epidermis is observed in
the employed model (Figure 4c and Supplementary Figure S2
online). It is unlikely that the release of IL-1a is mediated
through the adenosine receptor pathway(s) as ligands for both
adenosine receptors and adenylate cyclase failed to affect
secretion (Figure 3f and g). It appears that imiquimod has
effects upon cellular mechanisms which are yet to be
discovered.
The imiquimod-induced mouse model of psoriasis-
like disease represents exciting new opportunities for
exploring mechanisms of skin inflammation. The model is
clearly highly complex and involves multiple independent
pathways and mechanisms. Further characterization of the
model is needed to fully reveal its potential for improving our
understanding of human disease and testing new therapeutic
modalities.
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MATERIALS AND METHODS
Cell culture and viability assays
Pooled human primary keratinocytes were obtained from Life Technol-
ogies (Grand Island, NY) and maintained in EpiLife or Defined
Keratinocyte Serum-Free medium (Life Technologies) with gentamicin
(25mg ml 1, Life Technologies). Cells were adapted to Defined
Keratinocyte Serum-Free medium for at least 24hours before
treatments.
Mouse primary keratinocytes were isolated from newborn (24–
72 hours) mice. The epidermis and dermis were separated by
enzymatic digestion with 0.25% trypsin (Life Technologies) at 37 1C
for 45 minutes. The epidermal sheets were nutated to separate the
keratinocytes at 4 1C for 45 minutes. Cells were grown at 34 1C with
5% CO2 in Keratinocyte Serum-Free Medium (Life Technologies)
supplemented with epidermal growth factor (10 ng ml 1, Sigma-
Aldrich, St. Louis, MO), bovine pituitary extract (140mg ml 1, Life
Technologies), hydrocortisone (50mM, Sigma-Aldrich), calcium chlor-
ide (45mM), and gentamicin on rat tail type I collagen–coated plates
(BD Bioscience, San Jose, CA).
Cell permeabilization was determined by measuring release of
LDH (Cytotoxicity Detection kit, Roche Applied Science, Indianapo-
lis, IN).
Culture treatments and neutralization/inhibition experiments
Confluent cells were treated with medium only, imiquimod (Invivogen,
San Diego, CA), poly(I:C) (Sigma-Aldrich), and/or IL-1a (species
matched, PeproTech, Rocky Hill, NJ) at the indicated concentrations.
Activity of IL-1a was blocked using the neutralizing antibody MAB200
(R&D Systems, Minneapolis, MN) as described elsewhere (Olaru and
Jensen, 2010b). Control cells were treated with isotype-matched IgG2a
(R&D Systems). Adenosine signaling was modulated using the adenylate
cyclase ligand forskolin and the adenosine A2 receptor agonist CV 1808
(both from Santa Cruz Biotechnology, Santa Cruz, CA).
Real-time reverse transcriptase PCR
RNA isolation, reverse transcription, and real-time PCR primers for
relative expression analyses of human CXCL1, CXCL2, IL-1a, IL-1b,
IL-8, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are
described elsewhere (Olaru and Jensen, 2010b). The following
primers were used for the analyses of gene expression in mouse
cells: mCXCL1-F, 50-ACCCAAACCGAAGTCATAGC-30; mCXCL1-R,
50TTTCTCCGTTACTTGGGGAC-30; mCXCL2-F, 50CAGACAGAAGT
CATAGCCAC-30; mCXCL2-R; 50TTCCAGGTCAGTTAGCCTTG-30;
mGAPDH-R2A, 50GCCCAATACGGCCAAATCC-30; mGAPDH-F2B,
50CTTGTGCAGTGCCAGCC. Real-time PCR assays were validated
as previously described (Sanmiguel et al., 2009). GAPDH levels were
used for normalization of mRNA levels.
ELISA
Human CXCL1, CXCL2, IL-1a, and IL-1b were detected as described
elsewhere (Olaru and Jensen, 2010b). Mouse CXCL1 (also known as
KC), CXCL2 (alternative name: MIP-2), IL-1a, and IL-1b levels were
determined using ELISA Development kits from PeproTech according
to the manufacturer’s instructions.
Mice
C57BL/6J and IL-1R1 KO (C57BL/6 background) mice were obtained
from the Jackson Laboratory (Bar Harbor, ME) and bred in house in a
specific pathogen-free animal facility. All housing, breeding, and
experimental procedures involving mice were approved by the
Temple University Institutional Animal Care and Use Committee
and in compliance with the US Department of Health and Human
Services Guide for the Care and Use of Laboratory Animals.
In vivo imiquimod treatment and cytokine reconstitution
Mice were used at 8–12 weeks of age. KO background-matched
C57BL/6J control mice were matched for age and gender in each
experiment. Fur on the back of the mice was removed by shaving
followed by depilatory cream treatment. Cream was thoroughly
removed with water. Each of the following 2 days (day 1 and 2)
62.5 mg Aldara cream (5% imiquimod, Medicis, Scottsdale, AZ) was
applied to an approximately 2 3 cm area of the back. On day 4
back skin was collected for histology, immunohistochemistry, and
explant cultures. Control untreated mice were euthanized and skin
collected on day 1. For explant cultures four pieces of skin were
excised per mouse using circular punch biopsy tools (4 mm diameter
each), generating full thickness skin samples of identical surface area.
Each explant was incubated in 200ml tissue culture medium for
24 hours at 34 1C and the 4 cultures (per mouse) pooled. For cytokine
reconstitution, CXCL1 or CXCL2 (25 ng per mouse approximately
equivalent to 4 ng cm 2, PeproTech) was mixed into the imiquimod
cream and applied as described above on day 1 and day 2.
Histology and immunohistochemistry
Mouse skin was fixed in 4% formaldehyde, buffered in phosphate-
buffered saline, and processed for standard hematoxylin and eosin
staining at the Histotechnology Facility at The Wistar Institute
(Philadelphia, PA). For immunohistochemistry, mouse skin was
embedded in optimal cutting temperature compound and stored at
 80 1C until use. Cryosections (7mm) were fixed in acetone/methanol
(1:1) and incubated with normal mouse serum to reduce non-specific
binding. Tissue sections were incubated with rat anti-mouse Ly-6G/Ly-
6C antibody (BD Biosciences) overnight in a humidified chamber at
4 1C. Tissues were subsequently labeled with biotinylated mouse anti-
rat IgG2b antibody (BD Biosciences) for 1 hour at room temperature,
streptavidin-HRP (Lab Vision, Thermo Fisher Scientific, Fremont, CA)
for 30 minutes, and DAB Chromogen (Lab Vision). Tissue sections
were counterstained with Mayer’s Hematoxylin (Sigma-Aldrich).
Statistical analyses
Arithmetic mean and SD’s from one representative experiment of at
least three independent experiments (n¼ 2 per independent time-
point and treatment within each individual experiment unless stated/
indicated otherwise) are shown in figures. Significance was deter-
mined using the Student’s t test.
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